CLDX - Celldex Therapeutics Inc Stock Price, Fair Value and News

$26.42+1.44 (+5.76%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CLDX Price Action

Last 7 days

-1.6%

Last 30 days

-7.9%

Last 90 days

-25.1%

Trailing 12 Months

-5.7%

CLDX RSI Chart

CLDX Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-11.38

Price/Sales (Trailing)

67.97

EV/EBITDA

-13.1

Price/Free Cashflow

-10.98

CLDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CLDX Fundamentals

CLDX Revenue

Revenue (TTM)

25.8M

Rev. Growth (Yr)

7.12%

Rev. Growth (Qtr)

-69.54%

CLDX Earnings

Earnings (TTM)

-154.1M

Earnings Growth (Yr)

-10.09%

Earnings Growth (Qtr)

-17.52%

CLDX Profitability

EBT Margin

-548.45%

Return on Equity

-19.61%

Return on Assets

-18.72%

Free Cashflow Yield

-9.11%

CLDX Investor Care

Shares Dilution (1Y)

40.37%

Diluted EPS (TTM)

-2.58

CLDX Alerts

Point72 Asset Management, L.P. reported owning 2.5% of CLDX [2024-11-14]
1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	17.8M	25.6M	25.8M	0
2023	5.8M	8.1M	10.2M	13.1M
2022	1.1M	1.7M	2.3M	2.9M
2021	5.4M	8.6M	8.1M	505.0K
2020	4.9M	4.4M	4.5M	7.4M
2019	6.9M	4.8M	4.5M	3.6M
2018	15.3M	14.2M	11.2M	9.5M
2017	7.0M	9.5M	11.2M	12.7M
2016	6.3M	5.5M	6.7M	6.8M
2015	3.7M	5.2M	5.2M	5.5M
2014	2.1M	2.6M	2.7M	3.6M
2013	11.2M	9.3M	7.1M	4.1M
2012	9.2M	9.2M	10.0M	11.2M
2011	45.6M	44.6M	44.6M	9.3M
2010	0	25.7M	36.3M	46.8M
2009	0	0	0	15.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

CEO	Mr. Anthony S. Marucci M.B.A.
WEBSITE	celldex.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	148

Celldex Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Celldex Therapeutics Inc? What does CLDX stand for in stocks?

CLDX is the stock ticker symbol of Celldex Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Celldex Therapeutics Inc (CLDX)?

As of Wed Nov 20 2024, market cap of Celldex Therapeutics Inc is 1.75 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLDX stock?

You can check CLDX's fair value in chart for subscribers.

Is Celldex Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CLDX is over valued or under valued. Whether Celldex Therapeutics Inc is cheap or expensive depends on the assumptions which impact Celldex Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLDX.

What is Celldex Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, CLDX's PE ratio (Price to Earnings) is -11.38 and Price to Sales (PS) ratio is 67.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLDX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Celldex Therapeutics Inc's stock?

In the past 10 years, Celldex Therapeutics Inc has provided -0.219 (multiply by 100 for percentage) rate of return.